Literature DB >> 21413090

The herbal preparation Padma® 28 protects against neurotoxicity in PC12 cells.

Isaac Ginsburg1, Lea Rozenstein-Tsalkovich, Erez Koren, Hanna Rosenmann.   

Abstract

Padma® 28 is a multicompound herbal preparation based on the camphor formulas from traditional Tibetan medicine (TTM). It contains a variety of different secondary plant substances, which include terpenes and polyphenols such as flavonoids and tannins. As a rich source of antioxidant polyphenols, this herbal Padma 28 preparation seems to be a promising candidate for the treatment of degenerative diseases such as Alzheimer's disease (AD), a condition involving oxidative stress. Moreover, polyphenols have also been shown to mitigate AD neuropathology. The study investigated the protective effect of Padma 28 and of certain polyphenols on the neurotoxicity of PC12 cells induced by the neurotoxins: amyloid-beta (Aβ), glutamate, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3-nitropropionate (3-NP), known to be involved in AD, Parkinson's disease (PD), amyotrophic-lateral-sclerosis (ALS) and Huntington's disease (HD), respectively. The decrease in cell viability induced by each of the toxins was significantly attenuated by Padma 28 treatment. Also, a decrease in the oxidative capacity of PC12 cells treated with Padma 28 was noted, indicating that the decrease in cell viability induced by the toxins might have been the result of an oxidative stress which could be attenuated by Padma 28 acting as a potent antioxidant. Padma 28, which is available in Europe and USA, seems to be a promising candidate for the treatment of CNS diseases.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21413090     DOI: 10.1002/ptr.3459

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  7 in total

1.  Phytochemical characteristics, free radical scavenging activities, and neuroprotection of five medicinal plant extracts.

Authors:  Chia Lin Chang; Che San Lin; Guia Hung Lai
Journal:  Evid Based Complement Alternat Med       Date:  2011-08-10       Impact factor: 2.629

Review 2.  Secondary Metabolites with Antioxidant Activities for the Putative Treatment of Amyotrophic Lateral Sclerosis (ALS): "Experimental Evidences".

Authors:  Jamire M Silva; Michelangela S C Nobre; Sonaly L Albino; Lucas L Lócio; Agnis P S Nascimento; Luciana Scotti; Marcus T Scotti; João A Oshiro-Junior; Maria C A Lima; Francisco J B Mendonça-Junior; Ricardo O Moura
Journal:  Oxid Med Cell Longev       Date:  2020-11-24       Impact factor: 6.543

Review 3.  Angiomodulatory properties of Rhodiola spp. and other natural antioxidants.

Authors:  Dorota M Radomska-Leśniewska; Piotr Skopiński; Barbara J Bałan; Agata Białoszewska; Jarosław Jóźwiak; Dariusz Rokicki; Ewa Skopińska-Różewska; Anna Borecka; Agata Hevelke
Journal:  Cent Eur J Immunol       Date:  2015-08-03       Impact factor: 2.085

4.  The effect of anti-inflammatory and antimicrobial herbal remedy PADMA 28 on immunological angiogenesis and granulocytes activity in mice.

Authors:  Dorota M Radomska-Leśniewska; Piotr Skopiński; Marcin Niemcewicz; Robert Zdanowski; Sławomir Lewicki; Janusz Kocik; Ewa Skopińska-Różewska; Wanda Stankiewicz
Journal:  Mediators Inflamm       Date:  2013-06-24       Impact factor: 4.711

5.  The Tibetan herbal medicines Padma 28 and Padma Circosan inhibit the formation of advanced glycation endproducts (AGE) and advanced oxidation protein products (AOPP) in vitro.

Authors:  Ewa Grzebyk; Agnieszka Piwowar
Journal:  BMC Complement Altern Med       Date:  2014-08-05       Impact factor: 3.659

6.  Inhibitory actions of selected natural substances on formation of advanced glycation endproducts and advanced oxidation protein products.

Authors:  Ewa Grzebyk; Agnieszka Piwowar
Journal:  BMC Complement Altern Med       Date:  2016-09-29       Impact factor: 3.659

Review 7.  Angiogenesis modulation by exogenous antioxidants.

Authors:  Dorota Magdalena Radomska-Leśniewska; Barbara Joanna Bałan; Piotr Skopiński
Journal:  Cent Eur J Immunol       Date:  2017-12-30       Impact factor: 2.085

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.